Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

NCT03207178 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Refractory B Cell Malignancy

Interventions

BIOLOGICAL: Mixed CD19/CD20 CAR-T Transfer

Sponsor

Shanghai Longyao Biotechnology Inc., Ltd.

Collaborators

[object Object]
[object Object]